

GRIFOLS

Grifols and Inpeco joining forces to deliver transfusion medicine ‘lab of the future’

- *Alliance enables Grifols to provide total automation solutions to ensure transfusion-screening laboratories provide more efficient, effective and faster analyses of blood and plasma samples*
- *Combining Grifols’ leading diagnostic instrumentation, reagents and technical service with Inpeco’s open automation technologies will enable labs to modernize, upgrade and scale their operations quickly and seamlessly*
- *The broader diagnostic capabilities enhance Grifols leadership in developing and providing a complete set of automation solutions that optimize operations regardless of size, from small labs to large blood banks*

Barcelona, Spain, March 20, 2025 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines and innovative diagnostic solutions, today announced it has signed a strategic agreement with Inpeco, a global leader in total laboratory automation technologies, to provide transfusion medicine labs with complete, tailored instrumentation, robotics and software capabilities to modernize their operations and make them more efficient.

The partnership adds to Grifols’ global leadership in instrumentation, reagents and technical service that screens blood and plasma for possible pathogens as well as performs blood typing for safer transfusions. Grifols, whose technology analyzes tens of millions of donor samples each year, now complements its portfolio with Inpeco’s new open automation system FlexLab™ X, a combination of leading-edge robotics and software that will enable Grifols solutions to interconnect with, and expand within, existing and future lab footprints.

Specifically, Grifols will enhance its industry-leading analytical technologies known for their high throughput and precision with Inpeco’s iconic automation solutions that dispatch sample tubes to Grifols analyzers, among others, and then, after testing, route them to a refrigerated storage to further reduce manual intervention while guaranteeing full sample traceability. Digital dashboards provide real-time data on lab performance, while flexible architecture allows to adopt innovations still to come.

As part of their collaboration, the two companies are exploring areas in which their combined engineering expertise could deliver more value to transfusion medicine laboratories, which could include technologies that focus on sample pooling, analysis and transport.

GRIFOLS

“Grifols is providing the laboratory of the future,” said Antonio Martínez, president of Grifols Diagnostic Business Unit. “We are extremely pleased to join forces with Inpeco, two global lab technology leaders with a complete solution for labs of any size to fully equip their operations knowing they will have the most advanced and scalable technologies today and in the future.”

“At Inpeco, we believe that end-to-end automation is the key to eliminating errors in diagnostic processes,” said Riccardo Triunfo, CEO of Inpeco. “Especially in transfusion medicine, where precision is non-negotiable, our mission is to ensure that labs operate with the highest levels of safety, efficiency and accuracy. Our partnership with Grifols reinforces this vision, enabling laboratories to modernize their operations with confidence.”

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

Spain

Duomo Comunicación

Tel.: +34 91 311 92 89 – +34 91 311 92 90

Raquel Lumbreras (Tel. +34 659 572 185)

Raquel_lumbreras@duomocomunicacion.com

Borja Gómez (Tel. + 34 659 572 185)

Borja_gomez@duomocomunicacion.com

INVESTORS:

Grifols Investor Relations & Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

GRIFOLS

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

About Inpeco

Inpeco is the global leader in Total Laboratory Automation. The company's game-changing solutions combine open connectivity with full sample traceability to support secure test results and increase efficiency in clinical laboratories around the world. To date, more than 2,700 Inpeco systems have been shipped to 78 countries. Inpeco also provides automation for anatomical pathology labs and is developing solutions for blood banks and life sciences applications. The Group is headquartered in Novazzano, Switzerland, and operates a development and manufacturing facility in Italy, as well as sales and service offices in Europe, the United States and China.

For more information about Inpeco, please visit www.inpeco.com.

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.